Kylin, Purdue University, Purdue Research Foundation deal

Kylin received exclusive rights to commercialize the university's pRNA nanoparticle RNAi delivery technology. Kylin's lead compound is KT-104, a pRNA-based therapeutic that has been tested in mice to ...